Manager, Field Applications at Thermo Fisher Scientific
BIOGRAPHY
With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and differentiation, and to optimize iPSC-derived cell therapy production workflows.
Dr. Farah will discuss strategies to address a range of issues and bottlenecks in iPSC-derived cell therapy development. Using iPSC-derived CAR-NK (iNK) cells as an example, he will explore solutions for successful iPSC culturing and scale-up before sharing an optimized multi-step protocol to differentiate iPSCs to HSPCs to NK cells.